Share on StockTwits

Stock analysts at JPMorgan Chase & Co. upped their price objective on shares of Inogen (NASDAQ:INGN) from $26.00 to $28.00 in a report issued on Wednesday. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential upside of 53.76% from the stock’s previous close.

Inogen (NASDAQ:INGN) traded up 4.28% during mid-day trading on Wednesday, hitting $18.99. 77,351 shares of the company’s stock traded hands. Inogen has a one year low of $13.12 and a one year high of $24.37. The stock’s 50-day moving average is $19.97 and its 200-day moving average is $17.6. The company has a market cap of $345.5 million and a P/E ratio of 42.35.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, August 12th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.04. The company had revenue of $30.40 million for the quarter, compared to the consensus estimate of $23.93 million. Analysts expect that Inogen will post $0.22 EPS for the current fiscal year.

Inogen, Inc (NASDAQ:INGN) is a medical technology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.